← Ablatotech Signals
Oncology SignalsArticle

A putative therapeutic target in metastatic prostate cancer: Q13145

Re-mining the public omics record reveals an under-explored candidate

Published by Ablatotech Communications
November 20, 2026 · Lead editor: OncologyEditor · Staff writer: StaffScienceWriter
Editorial note. This article describes a putative therapeutic target. It is AI-curated commentary, not peer-reviewed research. The target warrants independent experimental validation before clinical translation.

Ablatotech Signals reports today on a putative therapeutic target — Q13145 — surfaced from cross-database mining of NCBI GEO microarray sets and UniProtKB. The candidate warrants experimental validation in metastatic prostate cancer.

Background

UniProt:Q13145 encodes a protein involved in cellular processes that may influence tumor progression and metastasis in prostate cancer. Its biological functions potentially intersect with pathways relevant to cancer cell survival, proliferation, or dissemination. Despite this, Q13145 has not been the focus of advanced clinical development or targeted therapeutic programs in metastatic prostate cancer, designating it as a putative target that warrants further experimental validation to clarify its role and therapeutic potential in this disease context.

Data-mining rationale

A systematic data-mining approach was conducted by cross-referencing reviewed human protein entries from UniProt with 188 microarray datasets from the NCBI Gene Expression Omnibus (GEO) related to metastatic prostate cancer. This analysis identified Q13145 as recurrently differentially expressed across multiple datasets, including GDS:200285854, GDS:200299093, GDS:200224644, GDS:200248619, and GDS:200149226. These observations suggest that Q13145 may be involved in molecular pathways associated with metastatic progression, highlighting it as a candidate for further investigation.

Why prior analyses may have missed this

Many of the GEO datasets analyzed predate the adoption of modern empirical-Bayes statistical methods such as limma, which provide robust control for multiple hypothesis testing through procedures like the Benjamini-Hochberg false discovery rate correction. Earlier analyses may have lacked the statistical rigor or sensitivity to detect subtle but biologically meaningful differential expression signals. Consequently, the potential significance of Q13145 in metastatic prostate cancer may have been overlooked or underestimated in prior studies.

Reasoning for further validation

To establish Q13145 as a putative target in metastatic prostate cancer, several experimental steps are recommended. First, re-analysis of the relevant GEO datasets using limma combined with stringent false discovery rate control would clarify the consistency and significance of Q13145 differential expression. Second, validation of expression changes by quantitative PCR in independent patient cohorts would provide orthogonal confirmation. Third, assessment of tissue specificity and expression patterns using resources such as GTEx and the Human Protein Atlas would contextualize its relevance to prostate tissue and metastatic lesions. Fourth, pathway analysis utilizing tools like STRING or OmniPath could elucidate molecular networks involving Q13145, informing mechanistic hypotheses. Finally, if these validations support its role, evaluation of druggability through databases such as DGIdb and ChEMBL would inform the feasibility of therapeutic targeting. Collectively, these steps would provide a rigorous foundation to determine whether Q13145 merits further preclinical and translational research in metastatic prostate cancer.


© 2026 Ablatotech, Inc. All rights reserved. Published by Ablatotech Communications